| Revenue growth | FY26 up 14% YoY; Q4FY26 up 19% YoY. |
|---|---|
| Margins | H1FY27 margins temporarily impacted; H2FY27 recovery to 17-18%. |
| Demand visibility | Strong growth in Ruby-Fill; biotech demand expected to improve. |
| Management confidence | High confidence in regulatory path for MIBG and pipeline acceleration. |
Growth
FY26 Revenue up 14% to ₹8,280 Cr; EBITDA up 8% to ₹1,326 Cr; Normalized PAT up 7% to ₹4,422 Cr.
Outlook
Guided H2FY27 EBITDA margins of 17-18%. Committed to net debt zero by 2030. Commencing commercial production on Line 3 late FY2027.
Risks
Short-term margin pressure in H1FY27 due to SPECT product supply shortages and lower production at CMO Montreal.
Earnings Call filed with BSE, NSE: JUBLPHARMA. Summary written with AI assistance from the document.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹1,071.95
- Market cap
- ₹17,074 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 48.5×Sector 50.4×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Business Update
Jubilant Pharmova announced the USFDA classified their Spokane facility as 'Voluntary Action Indicated' (VAI) following a recent inspection. This concludes the inspection review process.
Jubilant Pharmova Q1 FY27 Results: Net Profit ₹56.4 Cr, Down 45.0% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,229 Cr (+17.3% YoY) and net profit of ₹56.4 Cr (-45.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹56.4 Cr · -45.0% YoY
Jubilant Pharmova Q4 FY26 Results: Net Profit ₹119.3 Cr, Down 21.2% YoY
Jubilant Pharmova Ltd reported revenue from operations of ₹2,290 Cr (+18.7% YoY) and net profit of ₹119.3 Cr (-21.2% YoY) for Q4 FY26.
- Key figure
- Net profit ₹119.3 Cr · -21.2% YoY